Quick Facts

• Support for the Calving Period: Used to provide a source of calcium to cows around the time of calving (freshening).
• Calcium Level Maintenance: Intended to assist in maintaining serum calcium levels during the early post-calving period.

Bovikalc is an oral mineral nutritional supplement that functions as a source of calcium for dairy cows during the critical time surrounding calving. The use of this supplement is intended to provide support for the cow's transition into the lactation cycle.

The need for calcium increases substantially during the immediate post-calving phase due to milk production. Supplementation with Bovikalc helps to support the maintenance of blood calcium concentrations in fresh cows, which may otherwise experience a drop in these levels.

Its function is to contribute to the nutritional management of the cow during this phase, a period where there is a high demand for calcium. The goal of this supplementation is to assist in providing the necessary calcium to help the cow through the early stages of milk production.

This supplement is typically administered following delivery and is part of a broader nutritional strategy to promote normal function during the initial hours after calving. The product is not intended for use as the primary treatment for severe drops in calcium, but rather to offer a source of additional calcium to assist the cow's physiological processes.

Regulatory References

1. NIH MedlinePlus guidance

Eligibility: Who Can and Cannot Use Bovikalc?

The official eligibility profile for Bovikalc, an oral mineral nutritional supplement, defines strict rules for its use based on species, physiological status, and clinical condition. Regulatory documentation specifies that the product is intended exclusively for adult dairy cows during the critical periparturient period (around calving or freshening).

Population Eligibility Status	Official Regulatory Stance
Allowed Population	Adult dairy cows in the periparturient phase.
Contraindicated Groups	Humans; Cows with clinical signs of milk fever (hypocalcemia); Cows that are lying down (recumbent).

Administration is strictly contraindicated in cows displaying clinical signs of milk fever or those that are recumbent, as this often indicates an impaired swallowing reflex. The product is also explicitly restricted from being used as the primary, initial treatment for acute clinical hypocalcemia. Eligibility for use during both late pregnancy and early lactation is established, aligning with the product's defined application during the transition period. Furthermore, the bolus must not be administered if it is broken or damaged.

Interactions with other medicines and products

The official information for this product primarily details procedural and safety constraints related to its use, rather than listing formal drug-to-drug interactions with specific medicinal products or substance classes. No mechanistic basis, such as pharmacokinetic or pharmacodynamic effects involving metabolic enzymes or transporters, is documented in the product's regulatory interaction statements.

Condition and Administration-Based Constraints

Specific rules govern the concurrent or sequential use of Bovikalc with other forms of calcium supplementation, particularly parenteral injections. When the product is used to supplement calcium following an injection, strict timing must be observed:

• The first bolus should be administered 2 to 3 hours after the calcium injection.
• A subsequent bolus is typically given 12 to 15 hours after the first bolus.

Restrictions for Safe Use

For reasons of physical safety and to prevent complications like aspiration, the product has absolute restrictions related to the cow's physical state. The bolus must not be administered to animals that are down (paresis) or that display clinical signs of milk fever, as the normal swallowing reflex may be impaired under these conditions. These restrictions represent critical safety constraints linked to the method of oral administration.

No specific medicinal products or pharmaceutical classes are explicitly listed as interacting agents in the official regulatory product information.

Bovikalc is an oral calcium supplement bolus that provides readily available calcium ions to the systemic circulation. Its mechanism is a direct nutrient supplementation strategy, supplying calcium ions to increase the bioavailable systemic pool.

---

Dual-Phase Calcium Delivery Mechanism

The bolus contains two distinct calcium sources: calcium chloride and calcium sulfate. This composition engages a cascade that mediates a biphasic release profile in the alimentary system, involving rapid and sustained dissolution. The differential release modifies the molecular steps of ion absorption in the rumen.

---

Fast and Sustained Ion Regulation

The key pathway effect involves the modulation of plasma calcium ion levels following administration. Calcium chloride facilitates a high initial rate of calcium ion absorption, initiating a fast increase in blood serum levels. Calcium sulfate mediates a sustained release mechanism, promoting ongoing calcium ion absorption. This differential kinetic profile modulates the temporal availability of systemic calcium ions.

---

Influence on Systemic Calcium Dynamics

This delivery directly influences biological systems and processes where calcium signaling is essential, such as muscle contraction, nerve impulse transmission, and metabolic function. The direct supplementation affects the dynamics of systemic calcium levels, thereby influencing the system's inherent feedback regulation mechanisms.

Bovikalc is administered to dairy cows via the oral route as a solid, fat-coated bolus. The official instructions specify a concise, time-critical regimen that must be strictly followed immediately surrounding the calving event.

Administration Detail	Official Labeled Requirement
Route of Administration	Oral, via specialized applicator, ensuring the cow is standing.
Standard Dosing Schedule	A minimum course of two boluses is required: the first bolus is given immediately after calving, and the second bolus must follow 12 to 24 hours later.
High-Risk Regimen	For high-yielding cows or those with a history of previous low calcium levels, the regimen may be extended up to a maximum of four boluses, spaced at the same 12- to 24-hour intervals.

Administration of the bolus is contingent upon the cow's physical state. The product must only be given to animals that are standing and fully capable of swallowing, and it is explicitly not intended for use in cows that are recumbent. The bolus must be inserted using the dedicated Bovikalc applicator and gently guided past the tongue to ensure proper ingestion. The bolus must not be used if its protective coating is visibly damaged. This defined protocol establishes the product as an acute supplement, designed for a fixed, short-term frequency precisely timed to the onset of the cow's lactation cycle.

Research evidence / Overview of Studies for Bovikalc

This overview summarizes the available research regarding the clinical evaluation of Bovikalc, focusing on the types of studies conducted and the outcomes that researchers monitored, without offering clinical recommendations or instructions.

---

Evidence for Support of Periparturient Calcium Homeostasis

Research related to Bovikalc has primarily focused on its use in dairy cows around the time of calving, a period associated with temporary physiological imbalance due to the start of milk production. Studies explored whether supplementing the diet with this mineral bolus was associated with patterns of change in the animals' calcium levels.

The research base includes data from Randomized Controlled Trials (RCTs). The supplement was evaluated in these trials, where the research objective was to investigate patterns related to blood calcium stability during this acute transition.

Trials consistently described patterns where the bolus administration was associated with measurable shifts in serum calcium concentrations when compared to control groups during the first 24 to 48 hours post-calving. These short-term findings contribute to the broader evidence landscape of mineral support.

Primary Outcome: Blood Calcium Dynamics in Early Post-Calving Period

Research focusing on the immediate physiological strain or stress following calving typically monitored changes in biomarkers, such as total serum calcium and ionized calcium levels. This allowed researchers to observe patterns related to the initial availability of calcium in the blood following the supplement’s administration. Studies showed patterns related to these measurable short-term changes in the observed populations. These findings focus on the initial action of the bolus rather than the animal’s long-term health.

---

Long-Term Outcomes and Follow-up Duration in Research

In addition to monitoring immediate blood calcium dynamics, studies explored how the use of the supplement was associated with long-term health and productivity outcomes in dairy cows. These outcomes related to systemic or functional imbalance and were tracked over several weeks, ranging from 30 to 90 days in milk.

For general, untargeted herd populations, the research on major periparturient health events and productivity outcomes showed mixed findings. The evidence suggests that while data show patterns related to short-term calcium shifts, consistency across all groups remains uncertain regarding major long-term disease incidence.

---

Evidence in High-Risk Subpopulations

Research has also examined specific groups of dairy cows known to have higher nutritional demands or physiological strain, such as older cows (multiparous) or high-producing animals. These studies were evaluated in research exploring temporary physiological imbalance in these specific groups.

In these targeted settings, certain analyses described more consistent patterns of association between the supplement's use and the monitoring of clinical outcomes (e.g., health event frequency) or systemic or functional imbalance (e.g., calcium levels).

---

What the Research Indicates is Still Uncertain

One limitation is that follow-up durations were limited in some of the most consistent studies, which focused only on the initial 24 to 48 hours post-calving. This limits insight into the sustained duration of stability throughout the entire period of high calcium demand.

Additionally, evidence quality varies across studies, and for many later-stage outcomes, findings were mixed regarding the supplement's effect when evaluated in general cow populations. Long-term effects are not fully established, and comparative evidence is lacking for many later-stage outcomes. Research is ongoing to provide further insight into these areas.

The official product labeling strictly defines the environmental constraints and physical handling requirements for Bovikalc boluses.

Storage Conditions

Bovikalc must be stored at or below 30 C (86 F) and protected from humidity, as the product is susceptible to moisture. The boluses must remain stored in the original plastic tube until use.

Storage Restriction	Requirement
Temperature	Store at or below 30 C
Protection	Keep dry; susceptible to humidity
Integrity	Do not use if broken or coating is damaged

Handling and Disposal

The packaging is labeled as fragile and should be handled with care. The product is not for human use and must be kept out of the reach of children. Disposal of unused or expired product must be done by observing local and national regulations for waste.